BR112019000621A2 - anticorpos tgfss, métodos e usos - Google Patents

anticorpos tgfss, métodos e usos

Info

Publication number
BR112019000621A2
BR112019000621A2 BR112019000621-4A BR112019000621A BR112019000621A2 BR 112019000621 A2 BR112019000621 A2 BR 112019000621A2 BR 112019000621 A BR112019000621 A BR 112019000621A BR 112019000621 A2 BR112019000621 A2 BR 112019000621A2
Authority
BR
Brazil
Prior art keywords
protgfß1
garp
antibodies
selective antibodies
antigen binding
Prior art date
Application number
BR112019000621-4A
Other languages
English (en)
Inventor
J. CARVEN Gregory
Schurpf Thomas
Turner Katherine
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of BR112019000621A2 publication Critical patent/BR112019000621A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a anticorpos seletivos ao complexo protgfß1-garp, polinucleotídeos capazes de codificar os anticorpos seletivos ao complexo protgfß1-garp ou os fragmentos de ligação ao antígeno, células que expressam os anticorpos seletivos ao complexo protgfß1-garp ou os fragmentos de ligação ao antígeno, bem como vetores associados e anticorpos seletivos ao complexo protgfß1-garp ou fragmentos de ligação ao antígeno detectavelmente marcados podem ser utilizados para intensificar uma resposta imunológica em um indivíduo, por exemplo, contra um câncer.
BR112019000621-4A 2016-07-14 2017-07-14 anticorpos tgfss, métodos e usos BR112019000621A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US62/362,393 2016-07-14
US201662371355P 2016-08-05 2016-08-05
US62/371,355 2016-08-05
PCT/US2017/042162 WO2018013939A1 (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Publications (1)

Publication Number Publication Date
BR112019000621A2 true BR112019000621A2 (pt) 2019-04-24

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000621-4A BR112019000621A2 (pt) 2016-07-14 2017-07-14 anticorpos tgfss, métodos e usos

Country Status (13)

Country Link
US (2) US20190292254A1 (pt)
EP (1) EP3484499A4 (pt)
JP (2) JP7128801B2 (pt)
KR (1) KR102577551B1 (pt)
CN (1) CN110049773A (pt)
AU (1) AU2017294772B2 (pt)
BR (1) BR112019000621A2 (pt)
CA (1) CA3030862A1 (pt)
IL (1) IL264161A (pt)
MA (1) MA45690A (pt)
MX (1) MX2019000514A (pt)
SG (1) SG11201900200XA (pt)
WO (1) WO2018013939A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2919765C (en) 2013-08-01 2023-03-21 Universite Catholique De Louvain Anti-garp protein and uses thereof
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
TW202019957A (zh) * 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
CA3128042A1 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf.beta. and uses thereof
TW202128761A (zh) * 2019-10-25 2021-08-01 日商第一三共股份有限公司 抗garp抗體與免疫調節劑之組合
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20240301073A1 (en) 2021-07-14 2024-09-12 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
EP4410840A1 (en) * 2021-09-30 2024-08-07 Betta Pharmaceuticals Co., Ltd Bispecific antibody and application thereof
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
CN118829657A (zh) * 2023-02-06 2024-10-22 贝达药业股份有限公司 多特异性抗体及其应用
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
PT1838733E (pt) * 2004-12-21 2011-12-13 Medimmune Ltd Anticorpos direccionados a angiopoietina-2 e respectivos usos
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN103003424B (zh) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
EP3263601B1 (en) * 2012-10-02 2021-11-24 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
LT2981822T (lt) * 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
CA2919765C (en) 2013-08-01 2023-03-21 Universite Catholique De Louvain Anti-garp protein and uses thereof
CA2947967A1 (en) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016164468A2 (en) * 2015-04-07 2016-10-13 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to adamts13 and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
ES2951648T3 (es) * 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas

Also Published As

Publication number Publication date
JP2022153406A (ja) 2022-10-12
JP2019524094A (ja) 2019-09-05
AU2017294772A1 (en) 2019-01-31
AU2017294772B2 (en) 2024-05-02
CN110049773A (zh) 2019-07-23
IL264161A (en) 2019-02-28
WO2018013939A1 (en) 2018-01-18
US20190292254A1 (en) 2019-09-26
MX2019000514A (es) 2019-07-12
SG11201900200XA (en) 2019-02-27
US20210277100A1 (en) 2021-09-09
EP3484499A1 (en) 2019-05-22
MA45690A (fr) 2019-05-22
JP7128801B2 (ja) 2022-08-31
CA3030862A1 (en) 2018-01-18
KR20190034560A (ko) 2019-04-02
EP3484499A4 (en) 2020-05-13
KR102577551B1 (ko) 2023-09-11

Similar Documents

Publication Publication Date Title
BR112019000621A2 (pt) anticorpos tgfss, métodos e usos
CR20170079A (es) Agentes de unión a cd123 y usos de estos
BR112018068103A2 (pt) anticorpos gitr, métodos e usos
BR112018008904A2 (pt) anticorpos que se ligam especificamente a tim-3 e seus usos
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
PH12018500634A1 (en) Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
PH12016502505A1 (en) Bispecific t cell activating antigen binding molecules
MY184889A (en) T cell activating bispecific antigen binding molecules
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
BR112016022841A2 (pt) cadeia j modificada
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
UY35483A (es) Anticuerpos pac1 humanos
ECSP14020402A (es) Polipéptidos de unión a cx3cr1
BR112016004324A2 (pt) anticorpos
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
BR112017004495A2 (pt) variantes de celobiohidrolase e polinucleotídeos codificando as mesmas
BR112018070139A2 (pt) expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
AR095199A1 (es) Anticuerpos anti-cd52
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
AR104413A1 (es) Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
BR112017022635A2 (pt) anticorpo de igf-1r e seu uso para diagnóstico de câncer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]